<DOC>
	<DOCNO>NCT01533870</DOCNO>
	<brief_summary>Study healthy volunteer investigate effect Rifampin Pharmacokinetics NKTR-118 .</brief_summary>
	<brief_title>Study Healthy Volunteers Investigate Effects Rifampin Pharmacokinetics NKTR-118</brief_title>
	<detailed_description>An Open-label , fixed-sequence , 3-period , 3-treatment , Crossover Study Assess Effects Rifampin Pharmacokinetics NKTR-118 Healthy Subjects .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>Provision sign date , write informed consent prior studyspecific procedure . Male female ( nonchildbearing potential , nonlactating ) healthy volunteer age 18 55 year inclusive , suitable vein cannulation repeat venipuncture . Female volunteer must negative pregnancy test screen admission , must lactate , must nonchildbearing potential . Male volunteer willing use barrier contraception ie , condom , first day dose 3 month dose IP . The female partner use contraception period . Volunteers must BMI 18 30 kg/m2 , inclusive , weigh least 50 kg . Any clinically significant disease disorder ( eg , cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , malignant , psychiatric , major physical impairment ) , judge Investigator . Any clinically significant illness , medical/surgical procedure trauma , opinion Investigator , within 4 week first administration IP . Any clinically significant abnormality clinical chemistry , hematology , urinalysis result judge Investigator . Significant orthostatic reaction enrollment judge Investigator . Abnormal vital sign , 10 minute supine rest define protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy male female volunteer</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>NKTR-118</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Plasma AUC Cmax</keyword>
	<keyword>Plasma AUC0-t t1/2Î»z tmax</keyword>
</DOC>